Phase I/II trial of autologous activated macrophages in advanced colorectal cancer

European Journal of Cancer Part A

Volumn 32, Issue 11, 1996, Pages 1905-1911

  Eymard, J C ^a   Lopez, M ^b   Cattan, A ^a   Bouche O ^c   Adjizian, J C ^d   Bernard, J ^a  

^a INSTITUT JEAN GODINOT   (France)

^b INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d CRTS   (France)

Author keywords

Adoptive immunotherapy; Autologous activated macrophages; Metastatic colorectal carcinoma; Phase I II

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; FEVER; HUMAN; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL;

EID: 0009731041     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00233-X     Document Type: Article

References (33)

1. 1. Moertel CG, Reitemeier RJ. Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York, Harper and Row Publishers, 1969, 126-133.
2. 2. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989, 7, 425-432.
3. 3. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986, 4, 685-696.
4. 4. The Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
5. 5. De Gramont A, Krulik M, Cady J, et al. High dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988, 24, 1499-1503.
6. 6. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992, 69, 893-900.
7. 7. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 1984, 68, 233-255.
8. 8. Rosenberg SA, Lotze M, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316, 889-897.
9. 9. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of 652 patients with metastatic melanoma. N Engl J Med 1988, 319, 1676-1680.
10. 10. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 1988, 948, 151-173.
11. 11. Lewis CE, McGee JO'D. The Macrophage. New York, IRL Press, 1992, 315-357.
12. 12. Heppner GH, Fulton AM. Macrophages and Cancer. Boca Raton, CRC Press, 1988, 169-195.
13. 13. Wang BS, Lumanglas AL, Durr FE. Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene. Cancer Res 1986, 46, 503-506.
14. 14. Bartholeyns J, Lombard Y, Poindron P. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture. Anticancer Res 1988, 8, 145-152.
15. 15. Chokri M, Freundenberg M, Gallanos C, Poindron P, Bartholeyns J. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer Res 1989, 9, 1185-1190.
16. 16. Stevenson HC, Foon KA, Sugarbaker PH. Ex vivo activated monocytes and adoptive immunotherapy trials in colon cancer patients. Prog Clin Biol Res 1986, 211, 75-82.
17. 17. Andreesen R, Scheibenbogen C, Brugger W, Krauss S, Meerpohl H, Lohr G. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990, 50, 7450-7456.
18. 18. Faradji A, Bohbot A, Schmitt-Goguel M, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991, 33, 319-326.
19. 19. Streck R, Hurley E, Epstein D, Pauly J. Tumour cytolytic human monocyte-derived macrophages: a simple and efficient method for the generation and long-term cultivation as non-adherent cells in a serum-free medium. Res Immunol 1992, 143, 79-88.
20. 20. Lopez M, Fechtenbaum J, David B, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992, 11, 209-217.
21. 21. Lopez M, Martinache C, Canepa S, Chokri M, Scotto F, Bartholeyns J. Autologous lymphocytes prevent the death of monocytes in culture and promote, as do GM-CSF, IL3 and M-CSF, their differentiation into macrophages. J Immunol Methods 1993, 159, 29-38.
22. 22. Dunn PA, Tyrer HW. Quantitation of neutrophil phagocytosis using fluorescent latex beads. Correlation of microscopy and flow cytometry. J Lab Clin Med 1981, 98, 374-387.
23. 23. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a used chemotherapy agent. J Chron Dis 1961, 13, 346-353.
24. 24. Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 1986, 83, 5233-5237.
25. 25. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992, 13, 265-270.
26. 26. Mantovani A, Wang JM, Balotta C, Abdeljalil B, Botazzi B. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta 1986, 865, 59-67.
27. 27. Harwix S, Andreesen R, Ferber E, Schwamberger G. Human macrophages secrete a tumouricidal activity distinct from tumour necrosis factor-α and reactive nitrogen intermediates. Res Immunol 1992, 143, 89-94.
28. 28. Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazmder A. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 1986, 46, 994-998.
29. 29. Dumont S, Hartmann D, Poindron P, Faradji A, Oberling F, Bartholeyns J. Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer. Eur J Cancer Clin Oncol 1988, 24, 1691-1698.
30. 30. Kleinerman ES, Murray JS, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 1989, 49, 4665-4670.
31. 31. Galligioni E, Quaia M, Spada A, et al. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumour cells. Int J Cancer 1993, 55, 380-385.
32. 32. Kedar E, Klein E. Cancer immunotherapy: are clinical results discouraging - can they be improved? Adv Cancer Res 1992, 59, 245-322.
33. 33. Haddada H, Lopez M, Martinache C, Ragot T, Abina M, Perricaudet M. Efficient adenovirus-mediated gene transfer into human blood monocyte-derived macrophages. Biochem Biophys Res Comm 1993, 195, 1174-1183.